By Gilang Cahya 
Johns Hopkins Medicine scientists have identified a critical cellular mechanism that may explain why individuals with Loeys-Dietz syndrome, a rare inherited disorder affecting connective tissues, are particularly susceptible to developing life-threatening aneurysms at the root of the aorta. Their groundbreaking research, published on November 20th in Nature Cardiovascular Research, points to an overproduction of the protein Gata4 within vascular smooth muscle cells in this crucial region of the heart’s main artery. This discovery offers a significant step forward in understanding the progression of this complex condition and could pave the way for more targeted therapeutic interventions.
Loeys-Dietz syndrome, a multifaceted genetic disorder, impacts a range of bodily systems, including the craniofacial, skeletal, cutaneous, gastrointestinal, and cardiovascular structures. A hallmark of the syndrome is the development of aneurysms – abnormal bulges in artery walls that occur when the vessel’s diameter expands by 50% or more beyond its normal size. These weakened areas are at a significantly increased risk of tearing (dissection) or rupturing, leading to potentially fatal consequences. While aneurysms can manifest in any artery throughout the body, the aortic root, the segment of the aorta closest to the heart, emerges as the site of greatest vulnerability for patients with Loeys-Dietz syndrome.
The Central Role of Gata4 Imbalance
The research team at Johns Hopkins Medicine focused on genetically engineered mice that exhibited the characteristic features of Loeys-Dietz syndrome, including aortic root aneurysms. These mice carried a mutation in the Tgfbr1 gene, one of seven genes known to be implicated in Loeys-Dietz syndrome. The significance of this particular gene mutation was further underscored by its previous identification in human patients diagnosed with the syndrome. "The fact that the mutation of TGFBR1 was previously observed in patients with this condition adds confidence in the relevance of these findings to people with Loeys-Dietz syndrome," stated Hal Dietz III, M.D., the Victor A. McKusick Professor of Medicine and Genetics at the Johns Hopkins University School of Medicine, and a leading figure in Loeys-Dietz syndrome research.
Through meticulous analysis of vascular smooth muscle cells—the specialized cells that form the muscular layer of blood vessel walls—in the aortic root of these affected mice, the scientists observed an excessive production of the protein Gata4. This overabundance of Gata4 appears to be a critical factor predisposing these cells to the development of aneurysms.
A Collaborative Effort Across Institutions
To validate and contextualize their findings in mice, the Johns Hopkins team, led by Dr. Elena MacFarlane, Ph.D., assistant professor of genetic medicine at Johns Hopkins University School of Medicine, compared their data with that obtained from aortic cells collected from human patients with Loeys-Dietz syndrome. This crucial comparative analysis was made possible through the generous sharing of data by cardiac surgeons Albert Pedroza, M.D., Ph.D., and Michael Fischbein, M.D., Ph.D., from Stanford University.
"Identifying risk factors for aortic aneurysms in Loeys-Dietz patients has been a central focus of research," Dr. MacFarlane explained. She further elaborated on the clinical significance of the aortic root’s involvement: "In many patients, the aortic root is the canary in the coal mine, the first area of the aorta that dilates, indicating that the vessel is losing its integrity. Understanding what makes it vulnerable may help us better understand how Loeys-Dietz syndrome progresses and, in that manner, how it can be slowed or prevented with treatments."
The cross-species comparison was significantly enhanced by a sophisticated computational tool developed by Johns Hopkins scientist Genevieve Stein-O’Brien, Ph.D., M.H.S. This innovative tool allowed for the precise comparison of gene expression patterns across different tissues and species, providing a robust foundation for the study’s conclusions.
The Unfolding of the Discovery: A Timeline of Research
The journey to this significant discovery began with the foundational work of Emily Bramel, Ph.D., who was a graduate student in Dr. MacFarlane’s lab at Johns Hopkins and is now a postdoctoral fellow at the Broad Institute in Boston. Dr. Bramel initiated the current study by analyzing the genetically engineered mouse models. Her meticulous work provided the initial evidence of the cellular abnormalities associated with Loeys-Dietz syndrome in these animal models.
The subsequent comparison with human patient data, facilitated by the Stanford University team, was a critical juncture. This allowed the researchers to ascertain the direct relevance of their mouse model findings to human physiology. The development and application of Dr. Stein-O’Brien’s comparative gene expression tool by the Johns Hopkins computational biology team further streamlined this process, enabling a comprehensive and accurate analysis of the cellular data.
"We found that cells expressing high levels of Gata4 were present in higher numbers in the aortic root of mice and humans with Loeys-Dietz syndrome, begging the question of whether this contributes to the vulnerability for aneurysm formation," Dr. MacFarlane remarked, highlighting the pivotal observation that guided their subsequent investigation into the functional consequences of this Gata4 overexpression.
The Molecular Mechanism: A Blocked Degradation Pathway
The research further delved into the underlying molecular mechanism responsible for the Gata4 accumulation. Scientists discovered that smooth muscle cells harboring the Tgfbr1 mutation appear to be impaired in their ability to properly degrade excess Gata4 protein. This inability to clear the protein leads to its buildup within the cells.
While Gata4 is a vital protein involved in numerous developmental processes throughout the body, an excessive accumulation can prove detrimental. The Johns Hopkins team found that elevated levels of Gata4 lead to an overproduction of the angiotensin II receptor. This receptor is a key molecular target for a class of medications known as angiotensin II receptor blockers (ARBs), which are commonly prescribed for the management of high blood pressure.
Historical Context: Identifying Loeys-Dietz Syndrome
Loeys-Dietz syndrome itself was first identified in 2005 by Dr. Bart Loeys, M.D., Ph.D., then a researcher at Johns Hopkins, and Dr. Hal Dietz. Their work built upon a legacy of understanding connective tissue disorders at Johns Hopkins, notably the research of the late Victor McKusick, M.D., a pioneer in human genetics, whose systematic descriptions of Marfan syndrome, a condition with similarities to Loeys-Dietz syndrome, laid crucial groundwork. The identification of Loeys-Dietz syndrome marked a significant advancement in recognizing and characterizing this distinct genetic disorder.
Current Treatment Landscape and Future Therapeutic Avenues
Currently, Loeys-Dietz syndrome is estimated to affect approximately one in 50,000 individuals, according to reports from Loeys and Dietz. A primary class of medications utilized in the management of Loeys-Dietz syndrome are angiotensin II receptor blockers (ARBs). These drugs, commonly used for hypertension, have demonstrated efficacy in suppressing aneurysm progression in both mouse models and human patients with Marfan syndrome, thereby potentially mitigating the risks of vascular tears, premature mortality, and the need for surgical intervention.
The newly uncovered role of Gata4 overexpression and its link to the angiotensin II receptor pathway provides a compelling explanation for why the aortic root is particularly susceptible to dilation in patients with Loeys-Dietz syndrome. "The new findings could help us better understand why the aortic root is likely to dilate in patients with Loeys-Dietz syndrome," Dr. Dietz commented. He added, "Our research could eventually help refine treatment strategies for this condition, and potentially other vascular connective tissue disorders."
Implications for Treatment and Prevention
The discovery that excessive Gata4 accumulation, driven by the Tgfbr1 mutation, leads to increased angiotensin II receptor levels offers a tangible target for therapeutic development. While directly targeting Gata4 is considered unlikely due to its essential role in broader bodily development, the researchers are optimistic about targeting the upstream process that triggers the Gata4 excess.
"The process that triggers an excess of Gata4 could potentially be targeted by a drug," Dr. MacFarlane stated. "We just need to understand how it works." Future research will focus on unraveling the precise molecular cascade that leads to Gata4 accumulation in the context of the Tgfbr1 mutation. This deeper understanding could unlock novel therapeutic strategies aimed at preventing or slowing the progression of aortic aneurysms in Loeys-Dietz syndrome patients.
Broader Impact and Acknowledgements
The implications of this research extend beyond Loeys-Dietz syndrome, offering potential insights into other vascular connective tissue disorders where aortic root dilation is a significant concern. By elucidating the fundamental cellular mechanisms at play, the Johns Hopkins team is contributing to a broader understanding of vascular health and disease.
This significant research endeavor was a collaborative effort involving a multidisciplinary team of scientists. In addition to Dr. Bramel, Dr. MacFarlane, Dr. Dietz, and Dr. Stein-O’Brien, key contributors included Johns Hopkins scientists Wendy Espinoza Camejo, Tyler Creamer, Leda Restrepo, Muzna Saqib, Rustam Bagirzadeh, Anthony Zeng, and Jacob Mitchell, alongside collaborators from Stanford University, Dr. Pedroza and Dr. Fischbein.
The research was generously supported by funding from the National Institutes of Health (grants S10OD023548, R01HL147947, F31HL163924), the Marfan Foundation, the Loeys-Dietz Syndrome Foundation, and the Johns Hopkins Broccoli Center for Aortic Diseases. This collective support underscores the critical importance of continued investment in rare disease research and the pursuit of groundbreaking scientific discoveries.
